Changes in serum lipid levels during antihypertensive therapy.
The antihypertensive action of prazosin and propranolol, as well their effect on serum lipid levels, were evaluated in a crossover study in 20 men with untreated mild to moderate hypertension in a general practice environment. Both prazosin (7.5 +/- 0.5 mg/day) and propranolol (270 +/- 26 mg/day) produced a similar reduction in blood pressure over an eight-week period. The administration of propranolol also led to a reduction of the mean fasting high-density lipoprotein cholesterol concentration by 10.5% (P less than 0.01) and this effect was dose-related (r = -0.414; P less than 0.05). Prazosin treatment produced no changes either in the total or in the high-density lipoprotein cholesterol levels, but led to a reduction of the total triglyceride levels by 9.5% (P less than 0.05). These results suggest that the value of blood pressure reduction produced by high doses of beta-adrenoceptor blocking agents, such as propranolol, may be diminished by a potentially adverse effect of these agents on serum lipid levels. Conversely, alpha-adrenoceptor blocking agents may confer an added benefit in the treatment of hypertension.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000494:pharmacology*; D011433:Propranolol / Q000009:adverse effects / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D011897:Random Allocation; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008055:Lipids; D008075:Lipoproteins, HDL; D011799:Quinazolines; D014280:Triglycerides; D002784:Cholesterol; D011433:Propranolol; D011224:Prazosin